Table 4.
Complement pathways in TMA kidney sections from patients with various underlying clinical conditions
| Complement Pathway | Kidney Allografts (n=12) | Native Kidneys (n=30) | All TMA (n=42) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Recurrent aHUS (n=6) | Drug Toxicity (n=2) | Rejection (n=4) | aHUS (n=11) | STEC-HUS (n=1) | SLE/APS (n=10) | HSCT-TMA (n=6) | IgAN (n=1) | AAV (n=1) | ||
| Complement negative | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.0) | 1 (2.4) |
| Classical pathway | 1 (16.7) | 2 (100.0) | 3 (75.0) | 6 (54.5) | 1 (100.0) | 7 (70.0) | 5 (83.3) | 1 (100.0) | 0 (0.0) | 26 (61.9) |
| Both classical and lectin pathway | 5 (83.3) | 0 (0.0) | 1 (25.0) | 3 (27.3) | 0 (0.0) | 2 (20.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 12 (28.6) |
| Unknown pathway | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (7.1) |
Values are expressed as number (percentage). Drug toxicity refers to TMA in renal allograft in cases caused by toxicity of immunosuppressive therapeutics. Rejection refers to TMA in renal allograft cases during a rejection episode. APS, antiphospholipid syndrome; IgAN, IgA nephropathy; AAV, ANCA-associated vasculitis; NA, not applicable.